top of page

NeuroBo Pharmaceuticals to initiate Phase 1 Clinical Trial of DA-1726 for obesity

The FDA has cleared NeuroBo Pharmaceuticals’ Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide and cotadutide (another OXM analogue). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year.

The Phase 1 trial is designed to be a randomised, placebo-controlled, double-blind, sequential parallel group study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in subjects with obesity. Part 1 will be a single ascending dose (SAD) study, expected to enrol approximately 45 participants, randomised into one of 5 planned cohorts. Each cohort will be randomized in a 6:3 ratio of DA-1726 or placebo. Part 2 will be a multiple ascending dose (MAD) study, expected to enrol approximately 36 participants, who will be randomised into four planned cohorts, each to receive four weekly administrations of DA-1726 or placebo.

The primary endpoint will assess the safety and tolerability of DA-1726 by monitoring adverse events (AEs), serious adverse events (SAEs), treatment emergent adverse events (TEAEs) and AEs leading to treatment discontinuation. Secondary endpoints include the PK of DA-1726, assessed via serum concentrations over time and metabolite profiling at the highest doses of DA-1726. Exploratory endpoints will include the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI), among others.

"Clearance of the IND for DA-1726 allows us to proceed with the Phase 1 program for this novel GLP-1 and glucagon dual receptor, a potential new treatment to address the significant obesity market. As previously reported, preclinical evidence has shown that DA-1726 results in persistent weight loss in diet-induced obese mice and rats by reducing food intake while increasing energy expenditure,” said stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. “Additionally, in mouse models, DA-1726 showed superior weight loss compared to semaglutide (Wegovy) and its administration resulted in similar weight reduction while consuming more food compared to tirzepatide (Mounjaro). Based on these results, it is our belief that DA-1726 may have a better tolerability profile than currently available GLP-1 agonists due to its balanced activation of GLP1R and glucagon receptors. We look forward to dosing the first patient with DA-1726 during the first half of this year with an expected data readout in the first half of 2025."


bottom of page